Candida Fratazzi

With over 25 years’ experience in biomedical research, Dr. Fratazzi devised the SCIO concept. She founded BBCR Consulting in 2009, with the objective of actively contributing to the ongoing innovation in clinical development. Dr. Candida Fratazzi holds an higher degree in Immunology and is an Orphan disease expert. She worked in Cystic Fibrosis, Fabry disease, Gaucher’s disease, Multiple Sclerosis and more. Dr. Fratazzi consults to biotech, pharmaceutical, and medical device companies advising her clients on clinical/regulatory development road-maps and cost-efficient trial designs.


Board Member

Chair BBCR Consulting

Board Member Acuity Corp

Honorary Academic position at University College London (UK)

Scientific Advisory Board Hassuji Therapeutics

Scientific Advisory Board Venator Diagnostics

Chief Medical Officer PCUT BioPartners


Four successful therapeutics market approved worldwide:

– TECFIDERATM (dimethyl fumarate) capsules, Multiple Sclerosis; BiogenIdec

 – VPRIV™ (velaglucerase alfa for injection), Type 1 Gaucher Disease; Shire

 – REPLAGAL® (agalsidase alfa), Fabry Disease; Shire

– TYGACIL® (tigecycline IV), Antibiotic; Pfizer

Orphan Petition granted for rare diseases and orphan sub-populations


university.shield.small_.blue_ Cambridge Award for Pharmaceutical Consultant 2013, 2014, 2015

university.shield.small_.blue_ National Council of American Executives for Top Ranked US Executives 2014

university.shield.small_.blue_ Cambridge Business Hall of Fame for Pharmaceutical Consultant 2015

Education Background

university.shield.small_.blue_ Johns Hopkins University
harvard_shield_wreath-284x300 Harvard University

2000px-Imperial_College_London_crest.svg Imperial College London (UK)


MediVector: Vice President

Altus Pharmaceuticals: Senior Medical Leader

Shire: Senior Director

VI Technologies: Medical Officer

Wyeth- Pfizer: Medical Director


Biologics: Target & Therapy


Drug Design

Development and Therapy

Clinical Interventions in Aging


BIO Conference 2011 and 2012

ACRP 2012

MBC 2010 and 2011

GLG 2011

Big Data Analytics 2014-2015

DIA 2015

Biologics and Biosimilars 2015


Biomarkers in Drug Development Wiley, 2010

Clinical Development Strategy in Nuts and Bolts in Vaccinology. Blackwell, 2013

Clinical considerations in Statistical and Personalized Medicine. CRC, 2014

Over 50 scientific papers in peer review journals